Nektar Therapeutics (NKTR) FCF Margin (2010 - 2026)
Nektar Therapeutics' (NKTR) quarterly FCF Margin came in at 408.03% in Q1 2026, up 6095.0% year-on-year from 6.59% in Q1 2025, and down 36.94% quarter-over-quarter from 297.96% in Q4 2025.
Nektar Therapeutics (NKTR) FCF Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' FCF Margin history runs 17 years deep, the most recent figure standing at 408.03% for Q1 2026.
- On a quarterly basis, FCF Margin rose 6095.0% year-over-year to 408.03% in Q1 2026; TTM through Mar 2026 was 366.59%, a 16236.0% decrease from a year earlier, with the FY2025 full-year figure at 377.83%, down 19782.0% from the prior year.
- FCF Margin slipped to 408.03% in Q1 2026 per NKTR's latest filing, from 297.96% in the prior quarter.
- Across five years, FCF Margin topped out at 159.88% in Q4 2024 and bottomed at 468.98% in Q1 2025.
- The 5-year median for FCF Margin is 264.34% (2022), against an average of 290.26%.
- Across the five-year window, FCF Margin soared 36517 bps in 2022 and sank 24832 bps in 2025, its largest moves.
- Year by year, FCF Margin stood at 264.34% in 2022, then climbed by 25 bps to 197.97% in 2023, then increased by 19 bps to 159.88% in 2024, then plunged by 86 bps to 297.96% in 2025, then tumbled by 37 bps to 408.03% in 2026.
- Per Business Quant, the three latest NKTR FCF Margin figures stand at 408.03% (Q1 2026), 297.96% (Q4 2025), and 414.55% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Nektar Therapeutics | 2.04 Bn | 1.48 Bn | 3.16 Mn | -408.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -408.03% |
| Dec 31, 2025 | -297.96% |
| Sep 30, 2025 | -414.55% |
| Jun 30, 2025 | -409.62% |
| Mar 31, 2025 | -468.98% |
| Dec 31, 2024 | -159.88% |
| Sep 30, 2024 | -184.87% |
| Jun 30, 2024 | -161.30% |
| Mar 31, 2024 | -222.03% |
| Dec 31, 2023 | -197.97% |
| Sep 30, 2023 | -174.59% |
| Jun 30, 2023 | -252.13% |
| Mar 31, 2023 | -242.42% |
| Dec 31, 2022 | -264.34% |
| Sep 30, 2022 | -351.61% |
| Jun 30, 2022 | -351.04% |
| Mar 31, 2022 | -373.16% |
| Dec 31, 2021 | -629.51% |
| Sep 30, 2021 | -417.61% |
| Jun 30, 2021 | -304.21% |